Specifically, based on the present findings indicating a 7.2-fold increased risk of lymphoid malignancy in individuals with co-existent CHIP and MBL, we recommend that MBL screening be considered among individuals with CHIP, especially if the CHIP variants occurred in genes also related to CLL (e.g., TP53, SF3B1, and ASXL1). This evidence concerns the gene ASXL1 and B-cell chronic lymphocytic leukemia.